647 results on '"Park, Jinny"'
Search Results
2. Prognostic models for COVID-19 needed updating to warrant transportability over time and space
3. Transportability over Time and Space of Prognostic Models for Patient-Centered Decisions in COVID 19
4. Ultra-deep sequencing mutation analysis of the BCR/ABL1 kinase domain in newly diagnosed chronic myeloid leukemia patients
5. Large-scale validation of the prediction model risk of bias assessment Tool (PROBAST) using a short form: high risk of bias models show poorer discrimination
6. Differences in Clinical Outcomes Between Hydroxyurea-Resistant and -Intolerant Polycythemia Vera Patients
7. Fisetin Inhibits UVA-Induced Expression of MMP-1 and MMP-3 through the NOX/ROS/MAPK Pathway in Human Dermal Fibroblasts and Human Epidermal Keratinocytes
8. Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System
9. Using Different Data Sets to Test How Well Clinical Prediction Models Work to Predict Patients' Risk of Heart Disease
10. Clinical features and outcomes of hypocellular acute myeloid leukemia in adults: A Korean AML registry data
11. Unsaturated Fatty Acids Complex Regulates Inflammatory Cytokine Production through the Hyaluronic Acid Pathway
12. Abstract 4908: Study on Ca 2+-mediated regulation mechanisms on chemotherapy-induced peripheral neuropathy in multiple myeloma and non-Hodgkin lymphoma
13. Supplementary Methods, Supplementary Figure Legends, Supplementary Table from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
14. Supplementary Figure 1C from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
15. Supplementary Figure 3B from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
16. Supplementary Figure 2 from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
17. The Korean–Advance Directive Model and Factors Associated With Its Completion Among Patients With Hematologic Disorders
18. US and Dutch Perspectives on the Use of COVID-19 Clinical Prediction Models: Findings from a Qualitative Analysis
19. Effect of BCR::ABL1 transcript type and droplet digital polymerase chain reaction on successful treatment-free remission in chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitor
20. Comprehensive geriatric assessment in elderly patients with newly diagnosed aggressive non-Hodgkin lymphoma treated with multi-agent chemotherapy
21. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia
22. sj-docx-2-mdm-10.1177_0272989X231152852 – Supplemental material for US and Dutch Perspectives on the Use of COVID-19 Clinical Prediction Models: Findings from a Qualitative Analysis
23. sj-docx-1-mdm-10.1177_0272989X231152852 – Supplemental material for US and Dutch Perspectives on the Use of COVID-19 Clinical Prediction Models: Findings from a Qualitative Analysis
24. sj-docx-3-mdm-10.1177_0272989X231152852 – Supplemental material for US and Dutch Perspectives on the Use of COVID-19 Clinical Prediction Models: Findings from a Qualitative Analysis
25. A multicenter, open-label study for efficacy and safety evaluation of anagrelide in patients with treatment-naïve, high-risk essential thrombocythemia as a primary treatment
26. CDDO Induces Differentiation through PTEN Expression in HL-60 Cells
27. Cytogenetic profiles of 2806 patients with acute myeloid leukemia—a retrospective multicenter nationwide study
28. Pre-treatment blood inflammatory markers as predictors of systemic infection during induction chemotherapy: results of an exploratory study in patients with acute myeloid leukemia
29. Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study
30. Low-dose abdominopelvic computed tomography in patients with lymphoma: An image quality and radiation dose reduction study
31. Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in Korea
32. Generalizability of Cardiovascular Disease Clinical Prediction Models:158 Independent External Validations of 104 Unique Models
33. Clinical outcomes of early-progressed follicular lymphoma in Korea: a multicenter, retrospective analysis
34. Generalizability of Cardiovascular Disease Clinical Prediction Models: 158 Independent External Validations of 104 Unique Models
35. Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors
36. Additional file 1 of Prognostic models for COVID-19 needed updating to warrant transportability over time and space
37. Self-Reported Health-Related Quality of Life Predicts Survival for Patients with Advanced Gastric Cancer Treated with First-Line Chemotherapy
38. Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone
39. Prognostic Value of Metabolic Tumor Volume Estimated by 18 F-FDG Positron Emission Tomography/Computed Tomography in Patients with Diffuse Large B-Cell Lymphoma of Stage II or III Disease
40. Role of induction and consolidation chemotherapy in elderly acute myeloid leukemia patients
41. Clinical significance of Ki-67 and p53 expression in curatively resected non-small cell lung cancer
42. A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer
43. The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-label, observational study in Korea
44. Clinical Outcome and Predictive Factors in the Response to Splenectomy in Elderly Patients with Primary Immune Thrombocytopenia: A Multicenter Retrospective Study
45. Downregulation of matriptase suppresses the PAR‑2/PLCγ2/PKC‑mediated invasion and migration abilities of MCF‑7 breast cancer cells
46. Differences in the Cytotoxic Effects of Multi-Walled Carbon Nanotubes on Two- and Three-Dimensionally Cultured Human Neural Precursor Cells and Rat Brain Slices
47. Frequency of KRAS mutations in adult Korean patients with acute myeloid leukemia
48. Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy
49. Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma
50. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.